However, most patients with ALK-positive NSCLC who receive first-line crizotinib will progress within 1 year, usually because of insufficient disease control of the central nervous system.[2-4] Frequent crizotinib resistance and poor central nervous system efficacy are troubling for clinicians. The gene discussed is ALK; the disease is non-small cell lung carcinoma.